MedTrace Logo

Oblimersen in Treating Patients With Merkel Cell Carcinoma

NCT00079131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2013-06-04

No results posted yet for this study

Summary

This phase II trial is studying how well oblimersen works in treating patients with Merkel cell cancer. Biological therapies, such as oblimersen, may interfere with the growth of tumor cells and slow the growth of Merkel cell carcinoma (skin cancer).

Conditions

  • Recurrent Neuroendocrine Carcinoma of the Skin
  • Stage I Neuroendocrine Carcinoma of the Skin
  • Stage II Neuroendocrine Carcinoma of the Skin
  • Stage III Neuroendocrine Carcinoma of the Skin
  • Stage IV Neuroendocrine Carcinoma of the Skin

Interventions

BIOLOGICAL

oblimersen sodium

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Ki Chung · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00079131 on ClinicalTrials.gov